Back

Andros signs China topical-drug MOU as August revenue jumps 74.22%

Verifying
  • Andros Pharmaceuticals signed a China topical-formulation development MOU with Bonuo Kangyuan.
  • 74.22%: August revenue rose month over month to NT$1.62 million.
  • Andros said formal contracts, clinical plans and regulatory applications remain incomplete.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.